VIDEO: Larotrectinib shows efficacy, deep learning AI promise for finding NTRK fusions
Click Here to Manage Email Alerts
In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed recent research on NTRK fusion presented at the American Thyroid Association Annual Meeting.
"[Larotrectinib (Vitrakvi, Bayer)], which is an NTRK inhibitor, continues to show efficacy in NTRK fusions and good safety data," Cabanillas said.
She also discussed an oral presentation on deep learning AI software that has shown promise in identifying NTRK fusions.
"It takes a long time to be able confirm an NTRK fusion; it's like finding a needle in a haystack, but we have very really great data with NTRK inhibitors,” Cabanillas said. “These patients do very well and have durable responses, so we really want to find these patients."
Collapse
- Cabanillas M, et al. Poster 108. Presented at: American Thyroid Association Annual Meeting; Oct. 19-23, 2022; Montreal.
- Pelekanou V, et al. Oral 35. Presented at: American Thyroid Association Annual Meeting; Oct. 19-23, 2022; Montreal.
Click Here to Manage Email Alerts